66 results
PRE 14A
AXLA
Axcella Health Inc.
7 Aug 23
Preliminary proxy
4:15pm
of Cardiovascular, Renal and Metabolic Diseases Innovative Medicines and Early Development. Dr. Rondinone served in different roles in research and development … biopharmaceutical research and development experience qualifies her to serve on our board of directors.
Paul J. Sekhri has served as a member of our
8-K
EX-99.1
AXLA
Axcella Health Inc.
3 Aug 23
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:04am
million, compared to $17.1 million as of December 31, 2022.
R&D Expenses: Research and development expenses for the quarter and six months ended June 30 … , 2023 were $1.2 million and $2.7 million, respectively. Research and development expenses for the same periods ended June 30, 2022 were $16.9 million
8-K
EX-99.1
h73m2wqfcpqb m4w
4 May 23
Axcella Reports First Quarter Financial Results and Provides Business Update
4:33pm
8-K
EX-99.1
zzhese1r2
30 Mar 23
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
8:22am
8-K
EX-99.1
jr6re
1 Nov 22
Axcella Reports Third Quarter Financial Results and Provides Business Update
8:02am
424B5
ajtic9m9o
13 Oct 22
Prospectus supplement for primary offering
7:55am
8-K
EX-99.1
hdi27 0wa9e
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
7mku90dnfvjeob4bu5
25 May 22
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
rd7fojbw1zu3wx3
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
liwz5h9fj2x6s1
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
424B5
fnq9144ggcemx
16 Mar 22
Prospectus supplement for primary offering
8:00am